Hyderabad, India, Princeton, NJ, USA - Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as 'Dr. Reddy's') announced the launch of over-the-counter (OTC) Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7%, the generic equivalent of Extra Strength Pataday Once-Daily Relief, in the U.S. market, as approved by the U.S. Food and Drug Administration.
Dr. Reddy's Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% is an Antihistamine eye drop, indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander.
'This launch adds to our current portfolio in the OTC eye-care space which includes Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% and 0.1% strengths,' explains Milan Kalawadia, CEO, North America Generics, Dr. Reddy's Laboratories, Inc. 'The first-to-market launch is a testament to our deep capabilities in bringing store-brand equivalents of OTC brands in the U.S. market. We are excited to deepen our collaboration with our retail customers through this important addition to our store-brand portfolio.'
The Pataday brand had U.S. sales of approximately $69.9 million for the latest 52 weeks period ending December 27, 2025, according to NIQ data. Dr. Reddy's Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% is available in a 2.5 mL bottle.
About Dr. Reddy's
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of 'Good Health Can't Wait', we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include - USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity and governance.
Contact:
AISHWARYA SITHARAM
Email: AISHWARYASITHARAM@DRREDDYS.COM
PRIYA K
Email: PRIYAK@DRREDDYS.COM
(C) 2026 Electronic News Publishing, source ENP Newswire